Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL25181522 | 0.98 | CA14 (0.40) | CA14FPR3FPR2PRMT3CARM1 | |
| Trifluoroacetic Acid SCHEMBL27829960 | 0.90 | CA14 (0.44) | CA14FPR3FPR2PRMT3CARM1 | |
| SCHEMBL30360364 | 0.90 | CA14 (0.37) | CA14FPR3FPR2PRMT3CARM1 | |
| SCHEMBL380584 | 0.89 | CA14 (0.45) | CA14FPR3FPR2PRMT3CARM1 | |
| SCHEMBL9354393 | 0.87 | CA14 (0.44) | CA14FPR3FPR2AAK1HDAC6 | |
| SCHEMBL26900686 | 0.86 | CA14 (0.41) | CA14FPR3FPR2AAK1GPR88 | |
| SCHEMBL9354518 | 0.86 | CA14 (0.43) | CA14FPR3FPR2AAK1HDAC6 | |
| SCHEMBL7672284 | 0.86 | CA14 (0.43) | CA14FPR3FPR2AAK1HDAC6 | |
| SCHEMBL14735407 | 0.86 | CA14 (0.43) | CA14FPR3FPR2AAK1HDAC6 | |
| SCHEMBL15144523 | 0.86 | HDAC6 (0.37) | CA14HDAC6CA12CA1CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055118-A1 | VISIBLE LIGHT SENSITIVE PHOTOREMOVABLE PROTECTING GROUPS, PREPARATION PROCESS THEREOF, PHOTOACTIVATABLE CONJUGATES COMPRISING THEM AND USES THEREOF | HUN REN TERMESZETTUDOMANYI KUTATOKOEZPONT (HU) | 2026-02-26 | — | — | US | claimed |
| EP-4568943-A1 | VISIBLE LIGHT SENSITIVE PHOTOREMOVABLE PROTECTING GROUPS, PREPARATION PROCESS THEREOF, PHOTOACTIVATABLE CONJUGATES COMPRISING THEM AND USES THEREOF | HUN-REN TERMÉSZETTUDOMÁNYI KUTATÓKÖZPONT (HU) | 2025-06-18 | — | — | EP | claimed |
| CN-118307597-A | Mitochondrial-targeted hypoxia response prodrug as well as preparation method and application thereof | 中山大学 | 2024-07-09 | — | — | CN | claimed |
| CN-114672023-B | Preparation method of flexible hyperbranched water-soluble polyimide resin | 江苏环峰电工材料有限公司 | 2023-06-09 | — | — | CN | claimed |
| CN-114672023-A | Preparation method of flexible hyperbranched water-soluble polyimide resin | 江苏环峰电工材料有限公司广州分公司 | 2022-06-28 | — | — | CN | claimed |
| WO-2014045310-A1 | PYRIMIDO[5,4-D]PYRIMIDINE OR PYRIMIDINE DERIVATIVES COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER | ZOLLO MASSIMO (IT) | 2014-03-27 | — | — | WO | claimed |
| EP-4747248-A1 | COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION | Institute of Cancer Research: Royal Cancer Hospital (The) (GB) | 2026-05-27 | — | — | EP | disclosed |
| EP-4003988-B1 | 3,6-DIAMINO-PYRIDAZIN-3-YL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS PRO-APOPTOTIC AGENTS | SERVIER LAB (FR) | 2026-05-20 | — | — | EP | disclosed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | disclosed |
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-12617810-B2 | Prodrugs of STAT3 inhibitors | TVARDI OPERATING COMPANY, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12617805-B2 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | ENNOVABIO (ZHEJIANG) PHARMACEUTICALS CO., LTD. (CN) | 2026-05-05 | — | — | US | disclosed |
| US-20260108620-A1 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2 | SYNAFFIX BV (NL) | 2026-04-23 | — | — | US | disclosed |
| EP-0476515-A1 | New amino acid derivatives, a process for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-03-25 | — | — | EP | disclosed |
| EP-0410278-A1 | Renin inhibiting aminooligohydroxy-derivatives | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-01-30 | — | — | EP | disclosed |
| US-4921855-A | New Histidyl amino acid derivatives, and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-01 | — | — | US | disclosed |
| US-4902706-A | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as antihypertensive agents | G. D. SEARLE & CO. (US) | 1990-02-20 | — | — | US | disclosed |
| WO-1990000050-A1 | AMINOALKYLAMINOCARBONYL AMINODIOL AMINO ACID DERIVATIVES AS ANTI-HYPERTENSIVE AGENTS | G.D. SEARLE & CO. (US) | 1990-01-11 | — | — | WO | disclosed |
| EP-0349922-A2 | Aminoalkylaminocarbonyl aminodiol amino acid derivatives as anti-hypertensive agents | G.D. Searle & Co. (US) | 1990-01-10 | — | — | EP | disclosed |
| EP-0300189-A2 | New amino acid derivatives, processes for the preparation thereof and pharmaceutical composition comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12617810-B2 | Prodrugs of STAT3 inhibitors | STAT3, JAK2, STAT6 | CA14 1685/4885FPR3 1558/4885FPR2 2613/4885 |
| US-20260108620-A1 | ANTIBODY-CONJUGATES FOR TARGETING OF TUMOURS EXPRESSING TROP-2 | FUCA2, FUT6, FUCA1 | CA14 229/4885FPR3 2416/4885FPR2 1444/4885 |
| US-20260055118-A1 | VISIBLE LIGHT SENSITIVE PHOTOREMOVABLE PROTECTING GROUPS, PREPARATION PROCESS THEREOF, PHOTOACTIVATABLE CONJUGATES COMPRISING THEM AND USES THEREOF | XDH, XPA, HCCS | CA14 654/4885FPR3 286/4885FPR2 279/4885 |
| US-12617805-B2 | Codrug that disintegrates in intestine, preparation therefor, and use thereof | IRAK4, JAK1, VIP | CA14 2960/4885FPR3 1944/4885FPR2 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.